MARKET

RMTI

RMTI

Rockwell Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8949
-0.0088
-0.97%
Pre Market: 0.9025 +0.0076 +0.85% 08:07 05/06 EDT
OPEN
0.9300
PREV CLOSE
0.9037
HIGH
0.9400
LOW
0.8900
VOLUME
510
TURNOVER
--
52 WEEK HIGH
2.529
52 WEEK LOW
0.8300
MARKET CAP
83.75M
P/E (TTM)
-2.1705
1D
5D
1M
3M
1Y
5Y
Rockwell Medical, Inc. to Report First Quarter 2021 Financial and Operating Results on May 17, 2021
WIXOM, May 03, 2021 (GLOBE NEWSWIRE via COMTEX) -- WIXOM, Mich., May 03, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical...
GlobeNewswire · 3d ago
When the Price of Rockwell Medical #RMTI Talks, People Listen
Apr 28, 2021 (Stock Traders Daily via COMTEX) -- This is not EF Hutton, but it could be more #powerful. A picture speaks a thousand words, they say, and the...
Stock Traders Daily · 04/28 18:04
BRIEF-Rockwell Medical Announces Marketing Approval Of Triferic® Avnu™ In Canada
reuters.com · 04/27 12:29
Rockwell Medical gets marketing approval of Triferic AVNU in Canada
Rockwell Medical (RMTI) announces that its Triferic AVNU (ferric pyrophosphate citrate injection) received a marketing approval from Health Canada for the replacement of iron to maintain hemoglobin in adult patients
Seekingalpha · 04/27 12:00
24 Stocks Moving in Tuesday's Pre-Market Session
Gainers RiceBran Technologies (NASDAQ: RIBT) shares rose 29.1% to $1.20 in pre-market trading. RiceBran Technologies is scheduled to host a conference call on April 28th to discuss its Q1 financial results.
Benzinga · 04/27 11:05
Rockwell Medical Announces Marketing Approval of Triferic® AVNU™ in Canada
WIXOM, Mich., April 27, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today...
GlobeNewswire · 04/27 11:00
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 04/26 16:52
Moving Average Crossover Alert: Rockwell Medical (RMTI)
Rockwell Medical (RMTI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Zacks · 04/26 10:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RMTI. Analyze the recent business situations of Rockwell Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RMTI stock price target is 5.25 with a high estimate of 5.50 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 151
Institutional Holdings: 25.65M
% Owned: 27.41%
Shares Outstanding: 93.59M
TypeInstitutionsShares
Increased
33
3.55M
New
14
623.04K
Decreased
19
7.43M
Sold Out
10
220.94K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/Independent Director
John McLaughlin
President/Chief Executive Officer/Director
Russell Ellison
Chief Financial Officer/Executive Vice President
Russell Skibsted
Senior Vice President
Jim McCarthy
Chief Accounting Officer/Vice President/Controller
Paul McGarry
Chief Scientific Officer
Ajay Gupta
Vice President - Operations
Michael DeYoung
Other
Marc Hoffman
Other
Raymond Pratt
Independent Director
John Cooper
Independent Director
Robert Radie
Independent Director
David Domzalski
Independent Director
Mark Ravich
No Data
About RMTI
Rockwell Medical, Inc. is a biopharmaceutical company. The Company is targeting end-stage renal disease and chronic kidney disease with products for the treatment of iron deficiency and hemodialysis. The Company is also a manufacturer of hemodialysis concentrates for dialysis providers and distributors. The Company’s renal drug therapy, Triferic, supports disease management initiatives. Triferic is therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. The Company has developed multiple formulations of Triferic: Dialysate Triferic and Intravenous Triferic (I.V. Triferic). Dialysate Triferic is the therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.

Webull offers kinds of Rockwell Medical Inc stock information, including NASDAQ:RMTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RMTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RMTI stock methods without spending real money on the virtual paper trading platform.